Jonathon W. Senefeld
A5051337497- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Sports Performance and Training
- COVID-19 Impact on Reproduction
- Cardiovascular and exercise physiology
- Long-Term Effects of COVID-19
- Muscle activation and electromyography studies
- Heart Rate Variability and Autonomic Control
- High Altitude and Hypoxia
- Genetics and Physical Performance
- COVID-19 and healthcare impacts
- COVID-19 and Mental Health
- Muscle metabolism and nutrition
- Hormonal and reproductive studies
- Musculoskeletal pain and rehabilitation
- Motor Control and Adaptation
- Cardiovascular Effects of Exercise
- Doping in Sports
- Cardiac Arrest and Resuscitation
- Physical Activity and Health
- Sport Psychology and Performance
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Neuroscience of respiration and sleep
- Sports Analytics and Performance
- Sports injuries and prevention
University of Illinois Urbana-Champaign
2023-2025
Mayo Clinic in Arizona
2020-2024
Mayo Clinic
2019-2024
WinnMed
2019-2024
Mayo Clinic in Florida
2021-2023
Marquette University
2013-2021
Cooper Medical School of Rowan University
2021
Johns Hopkins University
2021
Cooper University Health Care
2021
American College of Surgeons
2015-2018
BackgroundConvalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such contains potentially therapeutic antibodies severe acute respiratory syndrome 2 (SARS-CoV-2) can be passively transferred recipient. Whether convalescent with high antibody levels rather than low is associated a lower risk of death unknown.MethodsIn retrospective study based on U.S. national registry, we determined anti–SARS-CoV-2 IgG in hospitalized adults...
BACKGROUND. Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent not yet been shown to be safe as a treatment COVID-19.
Abstract Importance Passive antibody transfer is a longstanding treatment strategy for infectious diseases that involve the respiratory system. In this context, human convalescent plasma has been used to treat coronavirus disease 2019 (COVID-19), but efficacy remains uncertain. Objective To explore potential signals of COVID-19 plasma. Design Open-label, Expanded Access Program (EAP) patients with Setting Multicenter, including 2,807 acute care facilities in US and territories. Participants...
<h3>Importance</h3> COVID-19 is a life-threatening illness for many patients. Prior studies have established hematologic cancers as risk factor associated with particularly poor outcomes from COVID-19. To our knowledge, no beneficial role anti–COVID-19 interventions in this at-risk population. Convalescent plasma therapy may benefit immunocompromised individuals COVID-19, including those cancers. <h3>Objective</h3> evaluate the association of convalescent treatment 30-day mortality...
Abstract To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials, matched control, case series, and report studies. Fixed-effects analyses demonstrated that hospitalized patients transfused with exhibited a ~57% reduction in mortality rate (10%) compared to matched-patients receiving standard treatments (22%; OR: 0.43, P < 0.001). These provide evidence favouring efficacy human as therapeutic agent patients.
Background: Convalescent plasma is the only antibody based therapy currently available for COVID-19 patients. It has robust historical precedence and sound biological plausibility. Although promising, convalescent not yet been shown to be safe as a treatment COVID-19. Methods: Thus, we analyzed key safety metrics after transfusion of ABO-compatible human in 5,000 hospitalized adults with severe or life threatening COVID-19, 66% intensive care unit, part US FDA Expanded Access Program plasma....
World-class athletes are substantively faster, wearing marathon racing shoes with technological advancements than other when competing in the marathon. Our findings suggest that advances footwear contributed to recent improvements finishing times among elite runners and record-setting performances. This investigation highlights importance of sports analytics may have broad implications for regulation running during competition.
The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response the rapid spread of severe acute respiratory syndrome 2 (SARS-CoV-2), causative agent COVID-19. While randomized clinical trials were various stages development and enrollment, there an urgent need for widespread access potential therapeutic agents. objective this study is report on demographic, geographical, chronological characteristics patients EAP, key...
The US Food and Drug Administration authorized COVID-19 convalescent plasma (CCP) therapy for hospitalized patients via the Expanded Access Program (EAP) Emergency Use Authorization (EUA), leading to use in about 500,000 during first year of pandemic USA.We tracked number CCP units dispensed hospitals by blood banking organizations correlated that usage with hospital admission mortality data.CCP per peaked Fall 2020, more than 40% inpatients estimated have received between late September...
Abstract Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests immunological differences may impact effectiveness of antibody-based treatments such convalescent plasma vaccines. Considering near-sourced likely reflects antigenic composition local viral strains, we hypothesize has a higher efficacy, defined by...
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have higher risk of persistent infection, severe disease, death from COVID-19. Despite the continued clinical use CCP to treat patients, optimal dose, frequency/schedule, duration has yet be determined, related best practices guidelines are lacking. A group individuals with expertise spanning infectious diseases, virology transfusion...
Abstract Biological sex is a primary determinant of athletic human performance involving strength, power, speed, and aerobic endurance more predictive than gender. This perspective article highlights 3 key medical physiological insights related to recent evolving research into the differences in physical performance: (1) gender are not same; (2) males females exhibit profound with outperforming events sports endurance; (3) endogenous testosterone underpins questions remaining on roles...